Market capitalization | $361.11m |
Enterprise Value | $145.43m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.63 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-85.74m |
Free cash flow (TTM) Free cash flow | $-66.05m |
Cash position | $223.85m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
11 Analysts have issued a Cabaletta Bio Inc forecast:
11 Analysts have issued a Cabaletta Bio Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.39 -0.39 |
52%
52%
|
|
EBITDA | -28 -28 |
71%
71%
|
EBIT (operating result) EBIT | -28 -28 |
65%
65%
|
Net profit | -25 -25 |
58%
58%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Nichtberger |
Employees | 103 |
Founded | 2017 |
Website | www.cabalettabio.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.